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Abstract: The thienopyridine antiplatelet agent clopidogrel is an effective drug for the prevention of vascular events. However, data 
has accumulated over time to suggest it is prone to significant interpatient variability. While there are several factors that contribute to 
this, one of the most important is variability in forming the active metabolite necessary for clopidogrel function. Several enzymes are 
involved in formation of this metabolite, and two, CYP2C19 and P-glycoprotein, appear to have alleles that both occur frequently in the 
population and have a clinically significant impact. Patients carrying these alleles can be identified, but it remains to be determined if 
this information is necessary or sufficient for risk stratification. Furthermore, if patients with high-risk alleles are identified, it is unclear 
how treatment should be adjusted.
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Introduction
Clopidogrel has become one of the cornerstone drugs 
in the treatment of atherosclerotic disease. Use of this 
antiplatelet agent, as monotherapy, is recommended 
for prevention of myocardial infarction in high risk 
patients  (eg,  patients  with  a  history  of  myocardial 
infarction (MI), stroke, or peripheral artery disease), 
as well as for secondary prevention of strokes.1–3 Its 
use, in conjunction with aspirin, is recommended to 
prevent acute coronary events in patients with recent 
stent placement or recent acute coronary syndrome.4,5 
It is one of the most prescribed drugs in the world. Yet 
it does not work for everyone.
Some patients who receive clopidogrel   nonetheless 
experience acute thrombotic events. In randomized 
controlled trials, patients undergoing PCI who receive 
both clopidogrel and aspirin still have an incidence of 
cardiovascular death, MI, or stroke in the next year 
of approximately 9%.6 It is, of course, unreasonable 
to  expect  a  drug  to  work  perfectly.  However,  the 
potentially fatal consequences of clopidogrel failure 
have lead researchers to investigate the reasons why 
the drug might fail. This has resulted in the concept of 
clopidogrel resistance.7,8
Unfortunately, there is no single, standard definition 
of clopidogrel resistance. Some limit their discussion 
to  the  aforementioned  treatment  failures,  clinically 
  significant  endpoints  that  occur  in  patients  taking 
  clopidogrel. Others use the term to refer to ex vivo 
  studies demonstrating that clopidogrel   suboptimally 
inhibits platelet aggregation in certain patients, as mea-
sured in a variety of assays.   Regardless of the approach, 
investigators have proposed numerous risk factors for 
poor outcomes in patients prescribed clopidogrel.
One of the factors identified as increasing risk for 
therapeutic  failure  is  genotypic  variation.    Several 
  different  genes  are  involved  in  the  processing  of 
clopidogrel, and genotypic variation of these is thus 
a  potential  source  of  phenotypic  variation.  This 
  article will review what is known about the effects of 
  genotypic variation on clopidogrel activity, and what 
options are available when genotypic variations are 
found in a patient.
Metabolism and Mechanism  
of clopidogrel
Clopidogrel is a thienopyridine pro-drug that requires 
bioactivation  before  it  can  achieve  its  antiplatelet 
effects9 (Fig. 1). Absorption of clopidogrel in the gut is 
opposed by the efflux pump P-glycoprotein, encoded 
by the ABCB1 gene. Once absorbed,   approximately 
85% of the drug is converted to an inactive metabolite 
by the action of esterases. The remaining 15% must 
undergo a two-step transformation process to become 
active.  The  first  step  produces  2-oxo-  clopidogrel, 
and  is  catalyzed  in  varying  proportions  by  the 
  cytochromes CYP2C19, CYP1A2, and CYP2B6. The 
second step, which produces the reactive metabolite, 
can be catalyzed by CYP3A4/5, CYP2B6, CYP2C19, 
or CYP2C9.
The reactive metabolite irreversibly binds to the 
P2Y12 receptor on the surface of platelets,   inhibiting 
its activation for the life of the platelet. The P2Y12 
  receptor  normally  binds  adenosine  diphosphate 
(ADP), and this interaction is one of the central events 
in   platelet activation.10 ADP binds both the P2Y1 and 
P2Y12 receptors. Stimulation of the   former initiates 
platelet  aggregation  by  activating  the    glycoprotein 
(GP) IIb/IIIa complex, but only weakly and   transiently. 
Stimulation of P2Y12 by ADP   amplifies the response, 
by not only potentiating the GP IIb/IIIa activation but 
also stimulating release of dense granules from the 
platelets. These granules contain more ADP, as well as 
other moieties that further activate GP IIb/IIIa. When 
GP IIb/IIIa is activated, it binds   soluble   fibrinogen and 
von Willebrand factor,   triggering aggregation. The net 
effect is that, while P2Y12 activation is not obligately 
required for   platelet activation, blocking ADP   binding 
of P2Y12 with clopidogrel does markedly reduce acti-
vation and subsequent platelet aggregation.
Genomic Variants and clopidogrel
With the multiple enzymes involved in   absorption and 
activation of clopidogrel, it is perhaps   unsurprising 
that there is significant population variation in the 
response to clopidogrel. Multiple enzymes   provide 
multiple opportunities for genomic   variation.   However, 
  variants in most potential metabolic enzymes, such 
as CYP3A4, CYP3A5, CYP1A2, CYP2B6, as well as 
genes for target proteins, such as P2RY12 (the gene 
for P2Y12) and ITGB3 (the gene for GP IIb/IIIa) have 
yielded little effect on either cardiovascular events 
or on platelet responsiveness when studied.11–13 Still, 
variants in two other enzymes, CYP2C19 and ABCB1, 
have  suggested  a  potentially  significant  impact  on 
clopidogrel efficacy.Clopidogrel pharmacogenomics
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Americans or Caucasians. As a consequence, Asians 
are  much  more  likely  to  be  poor  metabolizers  of 
clopidogrel.
The  presence  of  variability  in  response  to 
  clopidogrel as measured by platelet aggregation in 
response to ADP was first demonstrated by   Gurbel, 
et al.7 In this study, 15%–31% of patients could be 
described  as  clopidogrel  resistant,  depending  on 
the  duration  of  therapy.  They  did  not  attempt  to 
  ascertain why the patients had a suboptimal response. 
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Figure 1. Activation and mechanism of action of clopidogrel. Orally administered clopidogrel is absorbed in the intestine. The efflux pump P-glycoprotein 
(P-gp) can return some of the clopidogrel to the intestinal lumen. Once absorbed, much of clopidogrel is inactivated through the action of esterases in the 
liver. The remaining clopidogrel is activated via a two step process, catalyzed by several different cytochrome P450 (CYP) enzymes. The active metabolite 
will irreversibly bind the P2Y12 receptor on the surface of platelets, inhibiting platelet aggregation for the life span of the platelet.
CYP2C19
Over  20  allelic  variants  of  CYP2C19  have  been 
identified.14 The wild-type allele, following   typical 
nomenclature,  has  been  classified  CYP2C19*1. 
The  most  common  nonfunctional  alleles  include 
CYP2C19*2,  and  CYP2C19*3.  Most  of  the  other 
alleles reported are very rare and minimally func-
tional  at  best.  However,  another  common  allele, 
CYP2C19*17,  has  been  recently  described.  It  is  a 
gain-of-function allele, meaning it is associated with 
increased enzymatic activity. Specifically, this   latter 
allelic  variant  is  located  upstream  of  the    coding 
region, and is thought to increase the efficiency of the 
gene’s transcription. All of these alleles display con-
siderable inter-ethnic variation15–18 (Table 1). Taken as 
a whole, Asians have a higher probability of   carrying 
a   loss-of-function allele and a lower   probability of 
carrying a gain-of-function allele than either African 
Table 1. Allelic frequency of common CYP2C19 variants 
by race.
Race *1 *2 *3 *17
African 60%–64% 17%–20% ,1% 18%
Asian 58%–61% 30%–35% 5%–10% 2%–4%
Caucasian 63%–69% 13%–18% ,1% 18%–20%Terpening
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  Subsequently, many groups did attempt to address 
that  question.  CYP2C19  loss-of-function  alleles 
were first associated with poor clopidogrel respon-
siveness in 2006.19 Hulot, et al. treated 28 healthy 
patients with clopidogrel 75 mg daily for one week. 
The ability of each patient’s platelets to aggregate 
in the   presence of 10 µM ADP was measured daily. 
Twenty of these patients had the wild-type allele, 
while  8  were  heterozygous  for  the  CYP2C19*2 
allele. The 8   carriers of the nonfunctional allele on 
average did not achieve reduced platelet aggrega-
tion during the week of treatment with clopidogrel, 
whereas  the  wild-type  homozygotes  did.  These 
results have since been replicated in a wide variety of 
patient populations, with differing acuity, and using 
several different assays.
One study of note was that of Kim, et al.20 The 
authors  measured  circulating  clopidogrel  levels  in 
three different groups of eight Korean patients. Spe-
cifically, they compared wild-type CYP2C19 homozy-
gotes (*1/*1) with heterozygotes (*1/*2 or *3) and 
with patients homozygous for nonfunctional alleles 
(*2/*2 or *3). The authors noted a gene dose effect 
in the ability to metabolize a loading dose of clopi-
dogrel, with the nonfunctional homozygotes having 
2.9 fold higher area under the curve (AUC) of the par-
ent   compound than those carrying the wild-type allele, 
and  1.9  fold  higher AUC  than  those    heterozygous 
for the allele. This then translated into a differential 
  efficacy, with nonfunctional   homozygotes having 30% 
and 37% less platelet inhibition after a week of main-
tenance clopidogrel treatment than the heterozygotes 
and wild-type homozygotes,   respectively. Shuldiner, 
et  al.  corroborated  these  findings  in  an  Amish 
  population.21 In this study, CYP2C19*2 homozygotes 
(n = 9) had 35% and 42% less platelet inhibition than 
heterozygotes (n = 132) and wild-type homozygotes 
(n  =  288),  respectively,  in  response  to  a  week  of 
maintenance therapy with clopidogrel.   Furthermore, 
through multivariate   analysis, the authors concluded 
that the CYP2C19*2 allele accounted for 12% of the 
clopidogrel variation observed in that population.
In contrast to their findings with the CYP2C19*2 
allele, Shuldiner’s group noted that carriage of the 
CYP2C19*17 allele did not have an effect on   platelet 
inhibition  when  compared  with  the    wild-type. 
  However, Sibbing, et al. did find a gene-dose depen-
dent  effect  of  the  *17  allele.22  They  genotyped 
1524 patients who were to receive elective coronary 
stent placement as treatment for their coronary artery 
disease. Blood was sampled after a 600 mg loading 
dose of clopidogrel. Patients homozygous for the *17 
allele (n = 76) inhibited platelet aggregation more 
than those heterozygous for the allele (n = 546), who 
in turn had greater inhibition than wild type (n = 902). 
Possible reasons for the discordant results include the 
use of different assays to measure platelet inhibition, 
the use of different dosing regimens or differing dis-
ease state severity in the populations.
While  effects  on  platelet  aggregation  assays 
are informative, these do not necessarily equate to 
  clinical events. As a result, this has been a topic of 
considerable investigation. Two recent   meta-analyses 
have  looked  at  the  aggregate  data  concerning  the 
CYP2C19*2  allele.23,24  They  both  concluded  that 
  carriage of the nonfunctional allele was associated 
with an increased risk of a major adverse cardiovas-
cular event (MACE), with an odds ratio (OR) ranging 
from 1.29 to 1.96. Both meta-analyses also addressed 
stent  thrombosis,  with  ORs  for  this  event  ranging 
from  3.45  to  3.82.  One  of  the  meta-analyses  also 
suggested  a  gene-dose  dependence  on  the  adverse 
events. Specifically, heterozygotes for the *2 allele 
had ORs of 1.59 (95% CI; 0.88–2.88) for MACE and 
3.34 (95% CI; 1.84–5.93) for stent thrombosis when 
compared  to  patients  with  homozygous  *1  alleles. 
Homozygotes of *2 had ORs of 2.05 (95% CI; 1.15–
3.63) for MACE and 4.68 (95% CI; 1.55–14.11) for 
stent thrombosis.
Since  the  publication  of  these  meta-analyses, 
two  further  substudies  from  large  randomized  tri-
als  have  been  published.  In  a  substudy  of  the 
PLATO  trial,25  patients  with  any  loss-of-function 
allele  who  received  clopidogrel  had  a  higher  risk 
of  cardiovascular  death,  myocardial  infarction,  or 
stroke  than  those    without  a  loss-of-function  allele 
(11.2% vs. 10%). This   difference was not statistically 
significant, though (P = 0.25). If limited to only the 
first 30 days, the difference was significant (OR 1.37, 
95% CI; 1.04–1.82). The second study26 genotyped 
patients from two large trials, one targeting patients 
with  acute  coronary  syndromes27  and  the  other 
patients with atrial fibrillation.28 In neither instance 
did the   presence of loss-of-function alleles result in 
worsened outcomes while receiving clopidogrel when 
compared to those without loss of function alleles. Clopidogrel pharmacogenomics
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Even patients homozygous for   loss-of-function alleles 
did not seem to be at increased risk of clopidogrel 
  failure.  The  reasons  why  the  second  study  would 
have such starkly different outcomes when compared 
to the other trials are not   immediately obvious. The 
authors did state that the rates of PCI were very low 
in these trials, relative to the other trials. Also, much 
of the data in the meta-analyses come from cohort 
studies. The lack of a placebo arm in those studies 
could yield some confounding. Still, when taken as 
a whole, it is not unreasonable to   conclude that the 
presence of   loss-of-function alleles, especially when 
homozygous, does impart some increased chance of 
adverse clinical events in high-risk patients taking 
clopidogrel.
There  are  fewer  studies  that  address  gain-
of-function polymorphisms at the clinical level. Just 
as Sibbing, et al. found an increased effect of the *17 
allele on platelet inhibition, as described above, they 
also found an increased risk of bleeding.22   However, 
they  did  not  see  any  effect  on  clinical  events. 
Similarly, Wallentin, et al. found an increased risk of 
bleeding in acute coronary syndrome patients with 
the presence of a gain-of-function allele without any 
change in subsequent clinical event rate.25 In contrast, 
Pare, et al. reported an improvement in clinical event 
rates in patients carrying the *17 allele, without any 
increase in bleeding rate.26 Tiroch et al. also suggested 
reduced  target  lesion  revascularization  and  MACE 
incidence in acute MI patients who were carriers of 
the *17 allele, though they did not attempt to address 
bleeding risk.29 Thus, once again, we cannot draw 
hard conclusions as to whether the allele is beneficial 
or detrimental, but some caution seems advisable.
ABCB1
The ABCB1 (ATP-binding cassette B1) gene encodes 
the efflux pump, P-glycoprotein, also known as MDR1 
(multi-drug resistance 1 protein). It is expressed in 
several tissues throughout the human body, and is a 
member of a large family of transporter genes, who 
all have broad substrate specificity. Together, they are 
thought to help protect the body from a wide variety 
of xenobiotics. Pathophysiologically, this gene can 
be overexpressed in many cancer cells, resulting in 
resistance to many chemotherapeutic agents.
Over  50  different  polymorphic  sequences  have 
been identified in the ABCB1 gene.30 However, none of 
these are nonsense mutations. Thus all yield full length 
proteins. The best studied mutation is a shift from C to 
T  at  position  3435. This  particular  polymorphism, 
like  CYP2C19,  displays  considerable  inter-ethnic 
variation31,32 (Table 2). This is a synonymous mutation, 
meaning that the protein sequence is unaffected by the 
change in mRNA sequence. Studies to date have been 
conflicting, but overall suggest no significant differ-
ences in the amount of protein synthesized when either 
allele is translated.33 Similarly, there are conflicting 
data  regarding  mRNA  expression  and/or  stability, 
but the overall evidence suggests these are unlikely 
to  result  in  clinically  different  effects  for  the  two 
alleles.33 Thus, it is quite unclear why there should be 
any clinical difference based on this polymorphism. 
Still differences have been observed.
Taubert, et al. investigated the effect of the variant 
alleles on the circulating levels of clopidogrel and 
its  active  metabolite.34  Sixty  patients  undergo-
ing  PCI  were  randomized  to  receive  300,  600,  or 
900 mg loading doses of clopidogrel. Those patients 
who  were  homozygous  for  the  3435T  allele  had 
lower concentrations of both the parent and active 
metabolite of clopidogrel than carriers of the 3435C 
allele, unless a 900 mg loading dose was used. Thus, 
one  would  expect  impaired  platelet  reactivity  and 
worse clinical outcomes as a consequence. Spiewak, 
et al. did demonstrate an increased likelihood of an 
impaired  platelet  response  to  clopidogrel  among 
those  acute  coronary  syndrome  patients  who  were 
3435T homozygotes when compared to carriers of 
3435C, but did not observe any difference in clini-
cal outcomes.35 However, a substudy of the TRITON-
TIMI 38 trial, which also enrolled patients with acute 
coronary  syndrome  undergoing  PCI,  did  report  an 
increased risk of cardiovascular death, MI or stroke 
in  3435T  homozygotes  when  compared  to  3435C 
  carriers  (OR  1.72,  95%  CI;  1.38–2.82).36  Interest-
ingly,  the  FAST-MI  investigators  also  reported  an 
increased risk of cardiovascular death, MI, or stroke 
Table 2. Allelic frequency of common ABCB1 variants by 
race.
Race 3435c 3435T
African 79% 21%
Asian 58% 42%
Caucasian 45% 55%Terpening
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among 3435T homozygotes when compared to 3435C 
homozygotes.12 However, they reported that 3435CT 
heterozygotes  also  had  increased  risk  relative  to 
3435C homozygotes. This is the   opposite   conclusion 
that  the  TRITON-TIMI  38  substudy  observed.  If 
this weren’t confusing enough, both Wallentin, et al. 
and  Tiroch,  et  al.  reported  there  was  no  effect  of 
carrying  the  3435T  allele,  either  homozygously  or 
  heterozygously, on clinical endpoints.25,29 There are 
no immediately obvious reasons for the discrepant 
results. However, they are in keeping with the often 
contradictory results obtained in laboratory investiga-
tions of this polymorphism.
non-Allelic Variation of enzymes
Even if a patient has wild-type genes, activity of these 
genes can be modulated in multiple ways. Gremmel, 
et  al.  demonstrated  that  patients  age  75  and  older 
had higher incidences of residual platelet activity on 
clopidogrel than younger patients.37 They postulated 
that  this  could  be  secondary  to  generally  reduced 
cytochrome oxidase activity, yielding a lower amount 
of the active metabolite. Likewise, end stage liver 
disease would be expected to reduce cytochrome oxi-
dase levels and thus also significantly diminish the 
patient’s capacity to metabolize clopidogrel.
We can also modulate metabolic enzyme   activity 
through  use  of  concomitant  medications.  In  fact, 
drug-drug interactions could unmask subtle effects 
of allelic polymorphisms. An example of such has 
been  reported  with  CYP3A5.  Suh,  et  al.  reported 
that  homozygotes  for  a  poorly  functional  allele, 
CYP3A5*3,  did  not  display  any  difference  from 
noncarriers in platelet response to clopidogrel under 
baseline  conditions.  However,  when  these  patients 
were given itraconazole, a potent CYP3A4   inhibitor, 
clopidogrel’s  platelet  inhibition  was  markedly 
reduced in the homozygotes, but unchanged in the 
noncarriers.38
The drug interaction that has far and away gener-
ated the most discussion and investigation is the inhi-
bition of CYP2C19 by proton pump inhibitors (PPIs). 
In 2008, the American College of   Gastroenterology, 
American  College  of  Cardiology,  and    American 
Heart  Association  issued  a  consensus  document 
that recommended the use of PPIs if patients were 
using  dual  antiplatelet  therapy  in  order  to  reduce 
GI  bleeding  complications.39  That  same  year,  the 
OCLA  (Omeprazole  CLopidogrel  Aspirin)  study 
was    published,    describing  how  concurrent  use  of 
omeprazole  significantly  diminished  clopidogrel’s 
platelet  inhibition.40  Since  then,  there  has  been  a 
nearly constant barrage of studies on the topic, much 
of it contradictory.41 Reflecting the changing nature 
of the data, there have been four label changes to the 
Plavix® package insert in that time span. The most 
recent, and probably most applicable, data come from 
the COGENT trial.42 In this trial, 3761 patients were 
all  treated  with  dual  antiplatelet  therapy,  and  then 
randomized to receive omeprazole or placebo. Use 
of  omeprazole  significantly  reduced  GI  endpoints 
(OR 0.34, 95% CI; 0.18–0.63), without any apparent 
increase in cardiovascular events (OR 0.99, 95% CI; 
0.68–1.44). The trial was stopped early due to fund-
ing  issues,  and  did  not  utilize  cardiovascular  end-
points for their primary goals, but it does represent 
the largest trial to address the issue in a randomized 
fashion. Regardless, this topic will remain controver-
sial for some time.
One issue yet to be investigated well is the effect 
of PPI therapy on clopidogrel action in patients with 
genomic polymorphisms. While some may assume 
inhibitory effects would be additive, the converse is 
more likely. If a patient expresses a nonfunctional 
protein, it cannot be further inhibited. Thus, it will be 
interesting to see if heterozygotes, wild-type patients, 
or gain-of-function carriers might have differential 
inhibitory effects in the presence of PPIs.
coping with Genomic Variation
It  is  clear  that  patients  with  nonfunctional  alleles 
have increased risk of residual platelet activity and 
of   cardiovascular events, especially stent thrombosis. 
Patients with gain-of-function alleles may have reduced 
clinical events, but seem to have an increased risk of 
bleeding. What is less clear is whether obtaining the 
genotype of all potential patients, or even a   significant 
subset, offers enough   information to   justify the costs 
involved.  Genomic  tests  are    expensive,  ranging 
from $300–$500 per test, and typically not covered 
by  insurance.    Furthermore,  they  are  not  amenable 
to   simple point-of-care   analysis. The fastest of the 
current assays require at least a few hours to deliver 
results. Thus, any patient who requires clopidogrel 
acutely, such as during an emergent PCI, will not be 
able to obtain the results before initiating therapy.Clopidogrel pharmacogenomics
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Even for patients for whom time is not an issue, the 
relative importance of the information can be debated. 
As stated above, the CYP2C19*2 allele could only 
explain 12% of the variation in platelet   reactivity.21 
While several commercial assays do check for other 
loss-of-function  alleles,  few  of  the  current  assays 
detect the CYP2C19*17 allele and none detect the 
ABCB1 variants. Genotyping also has generally weak 
predictive  ability.  Hochholzer  et  al.  reported  that 
CYP2C19*2 carrier status was only 45% sensitive, 
and 75% specific for detecting high residual   platelet 
activity.  In  fact,  53.3%  of  CYP2C19*2  homozy-
gotes had normal platelet reactivity, and 22.4% of 
CYP2C19*1  homozygotes  had  impaired  platelet 
  reactivity.43 Thus, empiric strategies based solely on 
genotype could potentially alter therapy unnecessarily 
or fail to appropriately alter therapy, increasing risk 
of bleeding or clinical events.
It is clear that factors independent of the amount 
of  active  clopidogrel  also  have  a  large  impact  on 
the   phenotypic endpoint of platelet aggregation. For 
  example, type 2 diabetic patients are much more prone 
to having impaired platelet response to   clopidogrel 
when  compared  to  nondiabetic  patients.43,44  The 
underlying reasons are probably multifactorial. Insu-
lin  resistance  is  associated  with  increased  platelet 
reactivity.  Likewise,  obesity  is  highly  prevalent  in 
diabetics and has been shown independently to impair 
response  to  antiplatelet  agents.  Finally,  elevated 
  levels of pro-inflammatory mediators are common in 
diabetics, and are associated with increased platelet 
activation.
One  other  nongenotypic  factor  in  determining 
  clopidogrel effect worth mentioning is noncompliance. 
In a post-hoc analysis, Serebruany, et al. measured the 
levels of the main inactive metabolite of clopidogrel 
in over 600 patients ostensibly taking clopidogrel in 
the course of various clinical trials.45 Based on low 
levels  of  the  detected  metabolite,  22%  of  patients 
were  classified  as  noncompliant.  Obviously  this 
does not explain away all clopidogrel resistance, as 
many studies have been done with directly observed 
loading doses. However, given the magnitude of the 
impact of premature discontinuation of clopidogrel 
on stent thrombosis (OR up to 57) and mortality (OR 
up to 9.0), noncompliance may dwarf any impact of 
genomic variation.46,47 If nothing else, any alternative 
strategy to normal clopidogrel dosing in order to deal 
with genomic variation requires patient compliance. 
Thus, the importance of compliance must be clearly 
stated to patients and reinforced at intervals.
Taking  all  of  this  information  together,  the  use 
of  genotyping  as  the  sole  factor  in  determining  a 
patient’s  risk  for  subsequent  cardiovascular  events 
does not seem justified. There are those who would 
argue  that  relying  on  the  phenotypic  endpoint  of 
platelet  inhibition  would  be  a  preferable  strategy. 
These  ex  vivo  assays  are  much  cheaper  and  faster 
than genotyping, and theoretically should take into 
account  both  genotypic  and  clinical  influences  on 
platelet aggregation. However, there are several dif-
ferent  assays  available,  some  performed  under  a 
variety  of  conditions.  Each  assay  measures,  and  is 
sensitive to, different aspects of the cascade of events 
associated with platelet activation. Historically their 
results have been presented in a wide variety of man-
ners, eg, absolute percent reduction in platelet inhi-
bition  by  clopidogrel  when  compared  to  baseline, 
relative percent reduction by clopidogrel, or residual 
platelet  function  after  clopidogrel  treatment.  Only 
recently has the latter example, on-treatment platelet 
reactivity, come to be seen as the preferred measure 
for clinical purposes. A meta-analysis by Aradi, et al. 
reported that high on-treatment platelet reactivity was 
associated with a 3-fold increase in MI and a 4-fold 
increase in stent thrombosis.48 In part because of the 
lack of consensus, there have been few direct com-
parisons to see if any of the methods is superior to 
the  others. To  date,  the  best  comparative  evidence 
comes from the POPULAR study.49 In this study, high 
on-treatment platelet reactivity as measured by light 
transmittance  aggregometry  assays,  the  VerifyNow 
assay, and the Plateletworks assays all were able to 
predict the likelihood of a patient suffering death, MI, 
stent thrombosis, or stroke. The predictive accuracy 
was similar between the assays and modest, and none 
could predict the likelihood of bleeding. In contrast, 
Sibbing et al. did suggest that the Multiplate analyzer 
test could predict both stent thrombosis and   bleeding.50 
The authors did not compare this assay against oth-
ers  simultaneously  to  determine  relative  predictive 
  ability. However, based on these results and those of 
several others using different assays, a working group 
has proposed a series of standardized cut-off values 
for most of the commonly used assays.51 Thus, we 
are only now arriving at a point where we can rely on Terpening
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the risk assessment by the platelet assays. That said, 
the positive predictive power of these assays are uni-
formly low. It has been suggested that combining the 
predictive power of genotyping and phenotyping may 
improve overall risk assessment.52 This seems the most 
probable way for genotyping to be routinely used.
The major drawback to both genotyping and plate-
let assays is that we don’t know how to alter treatment 
to account for the results. Several options have been 
proposed over time. In broad categories, they include 
1) altering clopidogrel dose, 2) adding another agent 
(triple therapy), or 3) switching to a different drug 
(Fig. 2). Most of these strategies have not been assessed 
in terms of clinical outcomes, focusing instead on sur-
rogate markers of platelet aggregation. A fourth strat-
egy is sometimes overlooked, not using clopidogrel 
at all. Clopidogrel is sometimes inappropriately used 
for primary prevention or long-term secondary pre-
vention of cardiac events. With the exception of use in 
the aspirin allergic patient, neither indication is sup-
ported by clinical evidence or guideline.
Several  studies  have  investigated  alterations  of 
clopidogrel dosing. A randomized short-term doubling 
of the clopidogrel dose in all patients was tested in 
the CURRENT-OASIS 7 trial, alongside doubling the 
aspirin dose. In the population as a whole, there was 
no benefit to doubling either clopidogrel or aspirin, 
though there was an increase in bleeding rates with 
high dose clopidogrel.53 If one looked only at those 
undergoing PCI, there did appear to be a small benefit 
from a 600 mg loading dose, followed by six days 
of 150 mg clopidogrel.54 However, this too came at 
the cost of increased bleeding. The findings of   benefit 
from a doubled loading dose are in   keeping with a 
prior  meta-analysis.55  However,  they  still  suggest 
that a “one size fits all” strategy comes with trade-
offs,  increased  benefit  with  increased  risk.  Some 
investigators  have  tried  to  determine  if  an  altered 
loading dose of clopidogrel can help those patients 
carrying  loss-of-function  genotypes.  In  a  substudy 
of the PRINC trial, a higher loading dose of clopi-
dogrel improved platelet inhibition as measured by 
the VerifyNow analyzer in carriers of loss-of-function 
alleles.56  Likewise,  a  higher  maintenance  dose  for 
one week helped maintain platelet inhibition in these 
  carriers. Bonello, et al. also reported that repeated 
loading doses of clopidogrel could help most patients 
carrying the CYP2C19*2 allele to overcome high on-
treatment platelet reactivity, as measured by the VASP 
assay.57  However,  neither  study  investigated  long-
term clinical outcomes. While there are several trials 
underway to repeat the above findings on platelet inhi-
bition in a variety of populations and with a variety 
of assays, and a few clinical outcomes trials testing 
dosing strategies based on high on-treatment platelet 
reactivity (see Holmes, et al,58 for a discussion), there 
are only two current trials testing the effect of alter-
nate dosing guided by genotype on clinical outcomes, 
Altered Clopidogrel Dose
Repeat loading dose until satisfactory platelet reactivity
Empirically increase loading dose
Empirically increase maintenance dose (loss-of-function carriers/homozygotes)
Empirically reduce maintenance dose (gain-of-function carriers/homozygotes)
Triple therapy
Use of GP IIb/IIIa inhibitors during PCI
Add omega-3 fatty acids
Add cilostazol
Switch to different agent
Switch to prasugrel
Switch to ticagrelor
Figure 2. Treatment options for patients with genomic variant alleles.Clopidogrel pharmacogenomics
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Genotyping Infarct patients to Adjust and Normalize 
Thienopyridine treatment [GIANT;   Clinicaltrials.gov 
identifier NCT01134380] and Thrombocyte Activity 
Reassessment  and  Genotyping  for  PCI  [TARGET-
PCI; NCT001177592].
Some have advocated triple therapy as the norm, 
irrespective  of  genomic  status. A  meta-analysis  of 
triple therapy found that use of GP IIb/IIIa inhibitors 
on top of dual antiplatelet therapy offered benefits in 
patients with acute coronary syndromes.59 However 
these offer no benefits in unselected patients over the 
long term, and oral versions caused an increase in 
mortality. Thus, it is unlikely there will future studies 
based on genotype. Another add-on that has been stud-
ied is omega-3 fatty acids. In the OMEGA-PCI trial, 
their addition to dual antiplatelet therapy did improve 
platelet reactivity and light transmission aggregometry 
compared to placebo in patients undergoing elective 
PCI.60 While they did genotype their patients, they did 
not report the results based on genotype. The number 
of patients was also too small to determine clinical 
outcomes. Thus, the overall benefits in patients with 
loss-of-function  alleles  remain  mostly  speculative. 
Finally, cilostazol has been well studied as an add-on 
agent to dual antiplatelet therapy. It has been shown 
to reduce restenosis when added to clopidogrel and 
aspirin in both bare metal and   drug-eluting stents.61 
However, it does remain a question whether or not it 
affects MACE. There is some registry data to support 
a positive effect,62 but not any prospective randomized 
trials to date. It is also an open question as to whether 
patients  with  different  genotypic  variants  might 
have a greater benefit from cilostazol. CYP2C19 is 
involved in metabolizing cilostazol.63 Thus, carriers 
of loss-of-function alleles who might not benefit as 
much from clopidogrel, might have higher levels and 
larger effects from cilostazol. As with other options, 
there are no clinical data with dosing determined by 
genotype. However, there is at least one study com-
paring adding cilostazol to dual antiplatelet therapy 
against doubling the dose of clopidogrel in patients 
with  and  without  CYP2C19  variants.64  In  patients 
without loss-of-function alleles, there was no statis-
tical difference between the two strategies in terms 
of extent of platelet inhibition. In patients carrying 
at least one loss-of-function allele, cilostazol yielded 
greater  platelet  inhibition  and  lower  rates  of  high 
on-treatment platelet reactivity than high-dose clopi-
dogrel. It is worth noting that much of the research 
involving cilostazol was conducted in Asian nations, 
in populations that have much higher incidences of 
the different CYP2C19 loss-of-function alleles. Thus, 
extrapolating the benefits to other populations may 
not be straightforward.
Recently,  newer  antiplatelet  agents  have  been 
compared against clopidogrel. The only one   currently 
approved is prasugrel, also a thienopyridine. In the 
TRITON-TIMI  38  trial,  prasugrel  demonstrated 
superior reduction in ischemic events among acute 
coronary  syndrome  patients  when  compared  to 
  clopidogrel.65  However, this came at the cost of increased 
bleeding, including major bleeding. The bleeding was 
most prominent in those over the age of 75, under 
60 kg, or with a history of stroke. As noted above, car-
riers of loss-of-function alleles of CYP2C19 or of the 
ABCB1 3435T allele had increased risk when treated 
with  clopidogrel  compared  to  noncarriers.11,36  No 
increased risk was documented when those same pop-
ulations received prasugrel.36,66 Sorich et al. took that 
published data and integrated it to yield a more direct 
comparison.  They  suggested  that  prasugrel  offered 
a reduced incidence of cardiovascular death, MI, or 
stroke when compared to clopidogrel in carriers of 
CYP2C19 loss-of-function alleles (OR 0.57, 95% CI; 
0.39–0.83). In contrast, those without loss-of-function 
alleles  had  very  similar  results  when  compared  to 
clopidogrel (OR 0.98, 95% CI; 0.80–1.20).67 They did 
not compare those with gain-of-function alleles.
A second drug under consideration by the various 
regulatory agencies around the world is ticagrelor. It is 
a direct, reversible P2Y12 receptor inhibitor. It too had 
reduced cardiovascular death, MI, or stroke when com-
pared to clopidogrel, but with overall similar bleeding 
rates.68 Ticagrelor was numerically better than clopi-
dogrel in both carriers and noncarriers of loss-of-function 
alleles, though the latter just missed statistical signifi-
cance.25 Thus, ticagrelor appears to be a very promis-
ing alternative. However, ticagrelor has additional side 
effects than we expect from antiplatelet agents. Its use 
resulted in significantly higher rates of dyspnea and bra-
dycardia, and elevations in uric acid. These may limit its 
use in populations such as those with chronic obstructive 
pulmonary disease or gout. Also, compliance may even 
be more of an issue with ticagrelor than with clopidogrel. Terpening
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With its reversible receptor inhibition and twice daily 
  dosing, the risk of acute events may be higher with 
noncompliance.
Finally, with both new agents there are potential 
cost  considerations.  Prasugrel  is  more  expensive 
than brand clopidogrel, and it is reasonable to expect 
that ticagrelor will be as well if approved. A modest 
cost differential may be worth it if one can achieve 
improved  clinical  outcomes.  However,  clopidogrel 
will become generic in the near future. Once it does, 
there may be a strong economic incentive to identify 
those patients who need the newer agents, and those 
who will do similarly on the older generic drug.
conclusion
There is strong evidence of genotypic variation in the 
metabolism of clopidogrel, and that this variation has an 
impact on the phenotypic result of platelet inhibition. The 
evidence also supports an association between genotypic 
variants and clinical efficacy of clopidogrel. However, 
many factors beside   genotype also influence clinical 
response. Consequently,   genotyping cannot be used in 
isolation for risk stratification purposes, especially as 
the relative impact of heterozygous versus homozygous 
carrier status remains quite unclear. Since genotyping 
is time and labor intensive, it is therefore also costly. 
Thus,  there  is  debate  as  to  whether  the  incremental 
improvement in risk stratification is economically via-
ble. The debate is complicated by the fact that we do 
not know how to alter treatment to account for genomic 
  variations.  New  treatment  options,  such  as  prasugrel 
or ticagrelor, may render the question moot. However, 
current   trials do not support unequivocal superiority of 
these agents, and a widening gap in acquisition costs 
may drive further efforts to define an optimal popula-
tion to receive clopidogrel. Obtaining this evidence may 
ultimately provide a rationale to perform genotyping on 
a more frequent, if still selective, basis.
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